Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper 2 – Gastrointestinal tumours, colorectal

1890 - MIRACLE: Green tea extract versus placebo for the prevention of colorectal adenomas: a randomized, controlled trial


30 Sep 2019


Proffered Paper 2 – Gastrointestinal tumours, colorectal


Tumour Site

Colon and Rectal Cancer


Thomas Seufferlein


Annals of Oncology (2019) 30 (suppl_5): v851-v934. 10.1093/annonc/mdz394


T. Seufferlein1, T.J. Ettrich2, S. Menzler3, H. Messmann4, G. Kleber5, A. Zipprich6, S. Frank-Gleich7, H. Algül8, K. Metter9, F. Odemar10, T. Heuer11, U. Hügle12, R. Behrens13, L. Perkhofer2, C. Scholl14, K.L. Schneider14, F. Rohlmann15, R. Muche15, J.C. Stingl16

Author affiliations

  • 1 Department Of Internal Medicine I  , Ulm University Hospital, 89081 - Ulm/DE
  • 2 Department Of Internal Medicine I, Ulm University Hospital, 89081 - Ulm/DE
  • 3 Private Practice, Praxis Klinik Marburg, Marburg/DE
  • 4 Internal Medicine Iii, Augsburg University Hospital, Augsburg/DE
  • 5 First Department Of Medicine, Ostalbklinikum Aalen, 73430 - Aalen/DE
  • 6 Internal Medicine I, Martin-Luther-University Halle-Wittenberg, Halle/DE
  • 7 Private Practice, Onkologie Halle, Halle/DE
  • 8 Department Of Internal Medicine I, Technical University Munich, Munich/DE
  • 9 Department Of Gastroenterology, Alb-Fils-Kliniken, Göppingen/DE
  • 10 Internal Medicine, Amos Klinikum Bernburg, Bernburg/DE
  • 11 Internal Medicine I, St. Bernhard-Hospital, Kamp-Lintfort/DE
  • 12 Gastroenterology, Krankenhaus Köln-Holweide, Cologne/DE
  • 13 Private Practice, Gastroenterologisch-onkologische Praxisklinik, Halle/DE
  • 14 Research Division, Federal Institute of Drugs and Medical Devices, Bonn/DE
  • 15 Institute Of Epidemiology And Medical Biometry, Ulm University, Ulm/DE
  • 16 Centre For Translational Medicine, University Of Bonn Medical School, Federal Institute for Drugs and Medical Devices, Bonn/DE


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1890


Prevention of colorectal adenomas (CA) is likely to prevent colorectal cancer (CRC). Nutri- or chemoprevention of CRC is not yet established. NSAIDs show some benefit but also increase the bleeding risk. Agents with a more favourable benefit/risk ratio are desirable. Preclinical and small clinical trials suggest that epigallocatechingallate (EGCG), a major polyphenol in green tea, has a good safety profile and antineoplastic effects in the large bowel, but there are no data from large trials. MIRACLE enrolled 1001 patients to examine the effect of a three year intake of ECGC on the recurrence of CA after polypectomy.


Double-blinded, placebo-controlled trial, 41 recruiting German centers, recruitment 12/2011-6/2015. Patients aged 50-80 years who underwent polypectomy within the last 6 months and tolerated EGCG well during a one month run-in were randomized to standardized decaffeinated EGCG (150 mg bid) or placebo for 3 years. Primary endpoint: Incidence of metachronous CA at the 3 year follow-up colonoscopy. Secondary endpoints: Occurrence, number, localization, size, histological subtype of CA, frequency of CRC and biomarker. Strata: Study center and intake of low-dose aspirin (≤100 mg/d).


Clinical parameters were well balanced between the groups. Primary endpoint was analysed in the modified ITT set (modITT; n = 309 patients in EGCG, n = 323 in placebo group giving informed consent and undergoing 3 year follow up colonoscopy in the requested time frame). n = 102 patients in the EGCG and n = 103 in the placebo group were excluded due to missing follow up colonoscopy. Incidence of one or more CA after 3 year of placebo or EGCG 150 mg bid was 55.7 % and 51.1%, respectively (one sided adj. P = 0.077, adj. RR 0.904) in the modITT. In the per protocol set constituting all modITT patients completing the study without major protocol violations the respective figures were 54.3 % in the placebo and 48.3% in the EGCG group (one sided adj. P = 0.058, adj. RR 0.883). There were no safety issues and no major differences in AEs between EGCG and placebo during the randomized phase.


300 mg EGCG per day was well tolerated and showed a trend towards a preventive effect on CA in the large bowel though not statistically significant.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

Martin-Luther-Universität Halle-Wittenberg, Germany.


German Cancer Aid (Stiftung Deutsche Krebshilfe).


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.